SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026

Phase 1positiveiza-brenPositive

AI Analysis

Summary

SystImmune announced positive Phase 1 data for izalontamab brengitecan in EGFR-mutated NSCLC, with promising antitumor activity and tolerability supporting advancement to Phase 3 testing. The company will present the global data at WCLC Congress 2026.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Randomized dose-expansion cohort demonstrated promising antitumor activity and tolerable safety profile; 2.5 mg/kg D1D8 Q3W selected as recommended Phase 3 dose

Importance:5/10

Sentiment:

0.70

Phase 1 dataNSCLCEGFR-mutatedconference presentationdose selection

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on September 12, 2026 9:15 AM

Read Original